The small-molecule inhibitor nutlin-3 may be a viable treatment option for neuroblastoma patients with wild-type p53 activity, according to a new study published online November 10 in the Journal of the National Cancer Institute.
In this study in mice, Tom Van Maerken, M.D., Center for Medical Genetics, Ghent University Hospital in Belgium, and colleagues evaluated the antitumor efficacy of nutlin-3, a potent and selective antagonist of the p53–MDM2 interaction.